Syntegon has announced results for fiscal year 2025. The performance was driven by execution of its customer-focused growth strategy in structurally growing markets.

“2025 marks a year of outstanding performance for Syntegon. We made significant progress in our transformation into a leading strategic lifecycle partner for our customers, and in elevating our operational excellence,” said Torsten Türling, CEO, Syntegon. “As a result, Syntegon today operates a strong, scalable value creation platform and has set course for sustainable, long-term profitable growth.”

In 2025, Syntegon increased revenue by 10 percent to EUR 1.75 billion, while order intake reached EUR 1.86 billion, providing strong visibility into 2026. The strong revenue performance led to significant improvements in EBITDA and cash flow. EBITDA rose by 27 percent to EUR 282 million, corresponding to an EBITDA margin of 16.1 percent, an increase of 210 basis points compared to the prior year. Margin expansion was driven by higher volumes in attractive-margin segments, continued cost discipline, operational excellence, and improved project performance. The rebalancing of the company’s global manufacturing footprint, the establishment of an engineering hub in India, and sustained productivity improvements across facilities have additionally structurally supported margin expansion. Free cash flow increased by 51 percent to EUR 196 million, exceeding an already strong prior-year level. This performance was supported by robust EBITDA growth, a lean capital expenditure model, and disciplined working capital management.

In 2025, Syntegon made targeted investments in capacity expansion, innovation, and modern working environments. The company established a new Business Excellence Center in Stuttgart and significantly expanded its footprint, including the opening of a new Pharma Solid factory in Fellbach, Germany. In parallel, Syntegon further strengthened its R&D pipeline, allocating EUR 56 million to the development of next-generation line solutions. These investments position the company to drive sustainable growth in the years ahead.

Eros Carletti, CFO, Syntegon, said, “Across all key financial metrics, order intake, sales, profitability, and cash flow, we delivered meaningful improvements while maintaining a disciplined approach to investment and capital allocation. The consistent progress confirms that our strategy is firmly embedded in our operations and in the way we create value.”

Syntegon’s pharma business sustained strong growth momentum, with sales increasing by 22 percent versus the prior year. The company operates in structurally growing markets, driven by ongoing biotech innovation and an expanding biologics pipeline, particularly in injectable therapies. At the same time, increasingly stringent regulatory requirements are fueling demand for integrated, technologically advanced solutions. With the acquisition of Telstar, Syntegon strategically expanded its end-to-end pharmaceutical line solution portfolio and, in the first year of integration, delivered results ahead of plan.